Abstract: A system and its use for treatment of freight in a vacuum, having a chamber 1 for receiving a loaded container 9 having an external length CLa, an external width CBa and an external height CHa, wherein the chamber 1 has two side walls 11, 12 arranged opposite to a bottom 13 and top 14 and arranged opposite to a front wall 15 and back wall 16, and wherein a direction system XYZ is at right angles; and a conveying element 2 for parking and moving a container 9 relative to chamber 1 from a first position P1 outside the chamber 1 into a second position P2 inside the chamber 1; and a driving device 8 for moving between the first position P1 and the second position P2.

Abstract: A system and its use for treatment of freight in a vacuum, having a chamber 1 for receiving a loaded container 9 having an external length CLa, an external width CBa and an external height CHa, wherein the chamber 1 has two side walls 11, 12 arranged opposite to a bottom 13 and top 14 and arranged opposite to a front wall 15 and back wall 16, and wherein a direction system XYZ is at right angles; and a conveying element 2 for parking and moving a container 9 relative to chamber 1 from a first position P1 outside the chamber 1 into a second position P2 inside the chamber 1; and a driving device 8 for moving between the first position P1 and the second position P2.

Abstract: The present invention relates to a method of in vitro determining functional deficiencies in the lectin pathway of the complement system, the method comprises the steps of (a) diluting a mammalian sample of body fluid with a diluent comprising one or more inhibitors of the activation of the classical and the alternative pathways of the complement system; (b) activating the lectin pathway of the complement system in the sample obtained from (a); and (c) determining in the sample obtained from (b) the activation of one or more of the complement factors C3, C4, or one or more of the components of the C5-C9 complex. The invention furthermore relates to kits for use in connection with the above-mentioned method, the first kit comprises i) a first component comprising a carrier, one or more inhibitors of the classical and the alternative complement pathways and a diluent; and ii) a second component comprising one or more substances for activation of the lectin complement pathway and optionally an inert carrier.

Abstract: The present invention relates to a method of in vitro determining functional deficiencies in the lectin pathway of the complement system, the method comprises the steps of (a) diluting a mammalian sample of body fluid with a diluent comprising one or more inhibitors of the activation of the classical and the alternative pathways of the complement system; (b) activating the lectin pathway of the complement system in the sample obtained from (a); and (c) determining in the sample obtained from (b) the activation of one or more of the complement factors C3, C4, or one or more of the components of the C5-C9 complex. The invention furthermore relates to kits for use in connection with the above-mentioned method, the first kit comprises i) a first component comprising a carrier, one or more inhibitors of the classical and the alternative complement pathways and a diluent; and ii) a second component comprising one or more substances for activation of the lectin complement pathway and optionally an inert carrier.

Abstract: There is disclosed a method for determining the presence of endotoxin or an endotoxin like substance in a sample, as well as a monoclonal antibody and test kit useful in the method.

Abstract: In a method of determining the presence of an endotoxin or endotoxin-like material in a sample, a) a sample is incubated with a component of horseshoe crab amoebocytes lysate or haemolymph or a synthetic analogue thereof, b) the incubated mixture of the sample and the component or analogue resulting from step a) is reacted with an antibody raised against the component or analogue or against a reaction product of the incubation of step a), and c) the presence of endotoxin or endotoxin-like material in the sample is determined by detecting any bound antibody in the reaction mixture of step b). In the method either the component or analogue or the antibody or the endotoxin or endotoxin-like material is coupled to a solid support.